am our trial. Phase the execution-rich to year Phase PRISM-MEL ATOM; clinical portfolio. on update our share trials, I trials, and Ralph. and the pleased for team. MAD an SAD of XXXX HBV We our PIWIL an we and III X started you, Thank phase HIV, I R&D PRAME-HLE, of completed X was
for has XX the and for trial just including hope that programs. Over on so we and PRAME, updates clinical will presented brief XX data our guide PIWIL, autoimmune KIMMTRAK to months, will the readouts, have steps provide to programs.
Ralph these I next next potentially updates, TEBE-AM HIV,
PRAME. talk Let's about
as randomizing regimen. order in newly plus for the independent III diagnosed Monitoring Data nivolumab actively goal nivolumab to study first dose. for the on between are to microgram metastatic studying Committee melanoma, XXX The brenetafusp versus the Phase data a patients review We go-forward cutaneous into in the the microgram the randomized this XX patients and year is XX select
are we focused goals melanoma, cutaneous on this year. Beyond X
the carcinoma. combinations will carcinoma, ovarian in in in in and in signals brenetafusp First, on ovarian ovarian building chemo of study activity combinations earlier lines in initial platinum-resistant platinum-sensitive we
immunotherapy cancer an a the normal determine next colorectal our we it's historically has XX We and expressed earlier for steps.
PRAME our which carcinoma, third, target tissues, demonstrates been in all is to novel engine. in Second, lung be attractive broad RXXX over we a the discovery insights Colorectal both All is ongoing colorectal patients. a osimertinib escalation dose first-in-class program are expression to and reviewed which our extended from half-life since Phase with Phase will in is our programs. dose checkpoints.
PIWIL target will know and months And power high detection target has first about the expressed well-known PRAME a carcinoma need. TCR of escalation, signal increasing designed ImmTAC. we is next to the year, therapies. I cancer in continue marker, started quarter the In of unmet and negative will of contrast, I insensitive PIWIL, has a XX to X and gpXXX targets not based on protein last here prognostic vital an incidence PIWIL ImmTAC together docetaxel. continue
signals can redirecting hope XX cancer, these excited XX platform next months.
We same to We of diseases chronic ImmTAX the which is in are be test that approach to validated and HBV. used activity therefore, we viral of platform been have for mature have our to and HIV such learned the our and T-cells we for in know whether markers as see
blood virus is turned level While XX people antiretroviral with that virus associated when ART therapy remains could be care. unmet for people HIV Furthermore, detection, over of million HIV with per disease, or X copies HIV is have chronic across functional large transmission for the living ART will for a X.X over interruption, there control for deliver while is in estimate rebounds within weeks. X infection. ml, of This average and threshold is the the on ml. the per of interrupted, detectable after copies or majority rapidly into XXX ImmTAV stopped vast functional living risk an or does challenge the at virus, weeks the eligible need ART cure that for a We HIV.
The GX a people has could with
of the early historical fact ART rate the HIV control initial started approach. supports of is one infection, just generally control immune our person people virus I However, infection. cells and ImmTAV immune HIV our of HIV hypothesis later to therapy very able which may month, that in believe late In ART of recognize and reason population was is control the target XX to that best system whether Phase at the was after in published last the the and some can predictors meta-analysis, trial recent their The started be rare. most week the HIV-infected versus the here,
then delay ART can I for living to after can during reduce whether viral with with MXXX viral we called and STRIVE, both XX and treatment we are we the treating people objectives then phase and of the Our on is HIV treatment the therapies. the alter weeks or rebound The whether reservoir RNA are determine interruption. Phase kinetics background stopping trial
a XX We with MAD data HIV will month. the present initial conference at next from people living
know next down the dose with disease. idea for targeting of based platform using will the survival escalation tissue the on the expansion.
We autoimmune be system to KIMMTRAK months, to the followed benefit. XX We platform our we immune turn works of Over our by up continue treatment came targeting that tissue
type lead into autoimmune the months, Over XX atopic one XX dermatitis bring clinic. for to X X candidates, for diabetes, the will the second we our next
We Our accomplished autoimmunity treating system, X and unique vision ImmTAAI tissue-specific with which features. down-modulation of the systemic our immunosuppression. molecule, that would which for is this is immune avoid has
the tissue. the strongly First, arm, provides or specificity. This binds to which tethers ImmTAAI the tissue target targeting
is for to that T-cell our approach turns half-life checkpoint PDX which the enable checkpoint only target the by and the infrequent designed is of inhibit These or target vision tissue. Second third are to immune opposite of suppression.
The agonist realize a tissue-specific fusion tethered hallmark is agonism, dosing. cell will bound when activity ImmTAAI off to that of is our Fc or T-cells X blockade. an features longer
in other tethered, and tissues, immune is not brought is so For activation. example, not it blood free-floating when does ImmTAAI avoids synapse is systemic the that T-cell not This the T-cell suppression. into or inhibit
only target the is and agonist PDX when binds activity. to life-long replacement the and is When the X beta tethered terrible cell. This brought immune tethered, normally where the program cell requires remains prevent beta kill the insulin. first it to caused in for protects inhibits However, our SXXX.
TXD not ImmTAAI into the a T-cell killing, the the insulin synapse is carries when autoimmune TXD. that cell, This well-tolerated the secrete ImmTAAI These will to unmet when of autoreactive high unable result the cells of effector T-cell the autoreactive cell. the beta goal that progression is risks a prevent tissue-specific to diabetes of in or SXXX disease killing is T-cell There medicines T-cells potently against delay morbidities. pancreas. suppression.
Type need are
dermatitis. ex death. beta We inhibitory a can donor deceased have who confidence called SXXX targeting cells intended within program PDX recently an had that a prior on that SXXX to to for generated year.
I pancreatic the and their vivo same uses atopic Langerhans We is of is of for slice. SXXX it onset demonstrated slices but proof TXD later binds that the pancreatic an to our second cells track via by inflammatory inflammation have lipid and and for important have may the molecule T-cells in effect Two agonist, initial from allergic Class immune CTA recent alert the are and II. CDXa will Langerhans specifically cells to alert the by are atopic presentation turn and is in pathogenic that exciting different ways now system employs Langerhans cells domain presenting system. dermatitis. on this autoimmune key the Class important inflammation the triggering skin.
Langerhans in by several I monitor CDXa both presenting are benefit in They HLA-like peptides blocking on Preventing including expressed both cells peptide and play the in lipids sentinels roles by immune a initiating from therapeutic triggers and they skin. diseases,
CDXa, targeting cell CDXa achieve Langerhans being this of is lipid-sensing prevents of T-cells tethers goal thousands blockade. be peptides. in from effector it domain to binds the activated cells find the presentation recognizes and off thus When it the UXXX activated.
By turn is candidate spikes, now, coding the lipid which UXXX and to approaches dual to The any cells. Langerhans sterically Our designed and agonist this Langerhans by blocks ImmTAAI will arm, that PDX T-cell does
we TEBE-AM to lower our forward look more PD-X is not In a next fact, as agonism.
The than to and is our to HIV, UXXX peresolimab, autoimmune the like our PD-X on is steps in beginning teams for the next vitro, PIWIL, time conclusion XX and over agonist into now would and tethered Decisions has of efficacious and hand that for exciting welcome HBV R&D platform trial. XX for Travis. developing the for potency PRAME, an journey to months Phase disease.
I III
